$PRME News

Prime Medicine to Participate in Upcoming Investor Conferences

BMO Capital Initiates Coverage On Prime Medicine with Outperform Rating, Announces Price Target of $9

HC Wainwright & Co. Reiterates Buy on Prime Medicine, Maintains $8 Price Target

Prime Medicine, Inc. (PRME) Reports Q2 Loss, Misses Revenue Estimates

Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates

Prime Medicine Q2 EPS $(0.24) Beats $(0.26) Estimate, Sales $1.154M Miss $1.295M Estimate

Prime Medicine, Inc. (PRME) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease

Prime Medicine Says FDA Clears IND Application For PM577a, Investigational In Vivo Prime Editor For Wilson Disease; Initial Clinical Data Expected In 2027

Prime Medicine (PRME) Reaches Positive Resolution to Arbitration with Beam Therapeutics

Beam Therapeutics (BEAM) Faces New AATD Rival PM647 Ruling What Does It Signal Strategically?

Gene Editors, Including Powerhouse Beam Therapeutics, Diverge On Legal Battle

PRME Surges 15% After Winning Arbitration Against Beam — Clears Path To Human Trials For Its Gene-Editing Drug

Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics

Prime wins gene editing dispute; Saol claims latest post-Makary FDA reversal

Tribunal Declares Prime Medicine's PM657 Is Within It's "Field" As Defined By Agreement With Beam Therapeutics; Company Owes No Monetary Damages To Beam

Here’s Why H.C. Wainwright Upgraded Prime Medicine (PRME) To “Buy”

HC Wainwright & Co. Upgrades Prime Medicine to Buy, Announces $8 Price Target

Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)

Prime Medicine Says FDA Grants Regenerative Medicine Advanced Therapy Designation To PM359, Investigational Autologous Prime Edited Hematopoietic Stem Cell Therapy For Treatment Of p47phox-deficient CGD